MAP Kinase Kinase Kinases
"MAP Kinase Kinase Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Mitogen-activated protein kinase kinase kinases (MAPKKKs) are serine-threonine protein kinases that initiate protein kinase signaling cascades. They phosphorylate MITOGEN-ACTIVATED PROTEIN KINASE KINASES; (MAPKKs) which in turn phosphorylate MITOGEN-ACTIVATED PROTEIN KINASES; (MAPKs).
Descriptor ID |
D020930
|
MeSH Number(s) |
D08.811.913.696.620.682.700.559 D12.644.360.400 D12.776.476.400
|
Concept/Terms |
MAP Kinase Kinase Kinases- MAP Kinase Kinase Kinases
- Mitogen-Activated Protein Kinase Kinase Kinases
- Mitogen Activated Protein Kinase Kinase Kinases
- Kinases, MAP Kinase Kinase
- MAP3 Kinases
- Kinases, MAP3
- MAP Kinase Kinase Kinase
- MAPKKKs
MAPK-ERK Kinase Kinases- MAPK-ERK Kinase Kinases
- Kinase Kinases, MAPK-ERK
- Kinases, MAPK-ERK Kinase
- MAPK ERK Kinase Kinases
- MEK Kinases
- Kinases, MEK
- MEKKs
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase Kinases".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase Kinases".
This graph shows the total number of publications written about "MAP Kinase Kinase Kinases" by people in this website by year, and whether "MAP Kinase Kinase Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2016 | 1 | 0 | 1 |
2017 | 4 | 4 | 8 |
2018 | 6 | 5 | 11 |
2019 | 4 | 2 | 6 |
2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "MAP Kinase Kinase Kinases" by people in Profiles.
-
Virus-induced p38 MAPK activation facilitates viral infection. Theranostics. 2020; 10(26):12223-12240.
-
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019 06; 25(6):941-946.
-
Sarcoidosis occurring during BRAF/MEK inhibitors is associated with paradoxical ERK activation in Erdheim-Chester patients. J Eur Acad Dermatol Venereol. 2019 10; 33(10):e348-e350.
-
Dual-Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta-Activated Kinase 1 Suppression. Hepatology. 2019 05; 69(5):1946-1964.
-
Characterization of HCC Mouse Models: Towards an Etiology-Oriented Subtyping Approach. Mol Cancer Res. 2019 07; 17(7):1493-1502.
-
Severe fever with thrombocytopenia syndrome phlebovirus non-structural protein activates TPL2 signalling pathway for viral immunopathogenesis. Nat Microbiol. 2019 03; 4(3):429-437.
-
Creg in Hepatocytes Ameliorates Liver Ischemia/Reperfusion Injury in a TAK1-Dependent Manner in Mice. Hepatology. 2019 01; 69(1):294-313.
-
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. J Exp Clin Cancer Res. 2018 Dec 17; 37(1):318.
-
Resveratrol attenuates the MSU crystal-induced inflammatory response through the inhibition of TAK1 activity. Int Immunopharmacol. 2019 Feb; 67:62-68.
-
Identifying a panel of genes/proteins/miRNAs modulated by arsenicals in bladder, prostate, kidney cancers. Sci Rep. 2018 Jul 10; 8(1):10395.